Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5R01DA014502 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| DePaul University | OTHER |
| Hispanic Health Council, Inc. | OTHER |
| Case Western Reserve University | OTHER |
| National Institute on Drug Abuse (NIDA) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators seek to provide immunization for individuals who are at high risk of contracting hepatitis B virus (HBV) infection because of their illicit drug use. The investigators will be using the syringe exchange programs (SEPs) in Hartford and Bridgeport, CT and Chicago, IL to contact high risk individuals and refer them for vaccination. The primary purpose of the study is to compare the standard schedule of hepatitis B vaccination at 0, 1, and 6 months to an accelerated schedule of vaccination at 0, 1, and 2 months. The investigators hypothesize that the accelerated scheduling will result in improved completion rates without significant loss in vaccine efficacy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard vaccination schedule | Active Comparator | Standard dosing at 0, 1, and 6 months |
|
| Accelerated Schedule | Active Comparator | Accelerated dosing at 0, 1, and 2 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vaccination to prevent hepatitis B virus infection | Biological | Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule |
|
| Measure | Description | Time Frame |
|---|---|---|
| Vaccine Efficacy | 8 months from study enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Vaccine completion rate | 8 months from study enrollment | |
| Association of exchange status with completion | 8 months from study enrollment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert Heimer, Ph.D. | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hispanic Health Council | Hartford | Connecticut | 06106 | United States | ||
| DePaul University |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18541174 | Result | Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, Heimer R. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med. 2008 Jul;35(1):25-32. doi: 10.1016/j.amepre.2008.03.028. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
Not provided
Not provided
| NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
| Chicago |
| Illinois |
| 60614 |
| United States |
| Case Western Reserve Universtiy | Cleveland | Ohio | 44106 | United States |
| D004266 |
| DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |